Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Certepetide by Lisata Therapeutics for Glioblastoma Multiforme (GBM): Likelihood of Approval
Certepetide is under clinical development by Lisata Therapeutics and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...
Certepetide by Lisata Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Certepetide is under clinical development by Lisata Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Certepetide by Lisata Therapeutics for Peritoneal Cancer: Likelihood of Approval
Certepetide is under clinical development by Lisata Therapeutics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
Certepetide by Lisata Therapeutics for Ovarian Cancer: Likelihood of Approval
Certepetide is under clinical development by Lisata Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Certepetide by Lisata Therapeutics for Colon Cancer: Likelihood of Approval
Certepetide is under clinical development by Lisata Therapeutics and currently in Phase II for Colon Cancer. According to GlobalData, Phase...
Certepetide by Lisata Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Certepetide is under clinical development by Lisata Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...